TAIKO PHARMACEUTICAL CO., LTD. Logo

TAIKO PHARMACEUTICAL CO., LTD.

Manufactures OTC gastrointestinal medicine and leading infection control products.

4574 | T

Overview

Corporate Details

ISIN(s):
JP3442200006
LEI:
Country:
Japan
Address:
吹田市内本町三丁目34番14号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Taiko Pharmaceutical Co., Ltd. is a manufacturer and distributor specializing in pharmaceuticals and infection control products. The company operates through three primary business segments: Pharmaceutical, Infection Control, and Others. Its Pharmaceutical division is centered on its flagship product, Seirogan, an over-the-counter gastrointestinal medication with a history of over 100 years, used for treating symptoms like diarrhea and loose stools. The Infection Control division, a significant contributor to company revenue, develops and markets products including a leading brand of airborne disinfectants. The company is engaged in ongoing research and development to support its product lines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 08:35
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-08-08 08:34
Interim Report
半期報告書-第80期(2025/01/01-2025/12/31)
Japanese 197.8 KB
2025-04-01 08:45
Post-Annual General Meeting Information
臨時報告書
Japanese 22.1 KB
2025-03-28 07:36
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2025-03-28 07:35
Governance Information
内部統制報告書-第79期(2024/01/01-2024/12/31)
Japanese 22.1 KB
2025-03-28 07:33
Registration Form
確認書
Japanese 8.1 KB
2025-03-28 07:32
Annual Report
有価証券報告書-第79期(2024/01/01-2024/12/31)
Japanese 1011.8 KB
2024-08-09 08:34
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-08-09 08:33
Interim Report
半期報告書-第79期(2024/01/01-2024/12/31)
Japanese 210.9 KB
2024-05-10 08:37
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-05-10 08:35
Quarterly Report
四半期報告書-第79期第1四半期(2024/01/01-2024/03/31)
Japanese 164.9 KB
2024-04-01 08:14
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB
2024-03-28 07:30
Governance Information
内部統制報告書-第78期(2023/01/01-2023/12/31)
Japanese 22.1 KB
2024-03-28 07:28
Registration Form
確認書
Japanese 8.1 KB
2024-03-28 07:26
Annual Report
有価証券報告書-第78期(2023/01/01-2023/12/31)
Japanese 1.1 MB

Automate Your Workflow. Get a real-time feed of all TAIKO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TAIKO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TAIKO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.